51ce5fd7 047c Fb08 E063 6294a90a4fb6
Sevelamer Carbonate Tablet, Film Coated
Product Images NDC 87367-266
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 87367-266). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Insignamedex Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Figure 1)
This is a chemical structure of Sevelamer Carbonate showing the number of primary amine groups, cross-linking groups, and a large number to indicate an extended polymer network.*
Figure 2 Pro (Figure 2)
Figure 3 (Figure 3)
This is a graph showing the percentage of patients attaining a phosphorus reduction from baseline. The Y-axis represents the percentage of patients, while the X-axis shows the reduction in serum phosphorus in mg/dL. The graph also includes an active control group.*
Figure 4 (Figure 4)
This text describes a graph or chart showing the average change in phosphorus levels compared to the baseline for patients who completed 52 weeks of treatment.*
Sevelamer Label (Sevelamer Product Label 26612)
This is a description of Sevelamer Carbonate tablets. Each tablet contains 800 mg of Sevelamer Carbonate. The usual dosage information should be verified by consulting the package insert. The tablets should be stored at room temperature (25°C or 77°F) with excursions up to 15-30°C (59-86°F) permitted. It is important to keep the tablets in a tight container and protect them from moisture. This product is available in a pack of 270 tablets manufactured by InsignaMedex LLC. This medication is prescription-only and made in China. The revision date is May 2026.*
Table 1 Image (Table 1)
This text provides information on the starting dose of Sevelamer Carbonate for adult dialysis patients not taking a Phosphate Binder based on their serum phosphorus levels. The dosage varies depending on the phosphorus level, with different doses recommended for levels above 5.5 mg/dL and up to 7.5 mg/dL, and a higher dose for levels above 7.5 mg/dL. The recommended dosages are given three times daily with meals.*
Tablet 2 Image Pro (Table 2)
This is a table showing the recommended starting dosage and titration increment based on a pediatric patient's body surface area (BSA) in square meters. The starting dose per meal/snack and the titration increases/decreases per dose are provided for different BSA ranges, such as between 0.75 and below 1.2 square meters, and 1.2 square meters or above. The table specifies how much to titrate the dose by in grams based on the patient's BSA.*
Table 3 (Table 3)
This text provides information on the starting dose for dialysis patients switching from calcium acetate to sevelamer carbonate tablets. The table shows the dosage regimen for both calcium acetate and sevelamer carbonate tablets per meal.*
Tablet 5 (Table 5)
This text provides information on drug interactions involving sevelamer. It lists metoprolol and warfarin as oral drugs that were not affected by sevelamer when taken together. However, it advises separating the administration of ciprofloxacin and mycophenolate mofetil from sevelamer by at least 2 hours and 6 hours respectively to avoid interactions.*
Table 6 (Table 6)
This table displays the mean serum phosphorus levels in milligrams per deciliter (mg/dL) at both the baseline and endpoint for patients treated with Sevelamer Hydrochloride (N=81). The baseline value at the end of washout was 8.4 mg/dL, while at the endpoint it was 6.4 mg/dL. The change from baseline to endpoint was statistically significant within the treatment group, with a p-value of less than 0.0001.*
Tablet 7 (Tablet 7)
This text provides a table showing the mean serum phosphorus levels (measured in mg/dL) and ion product at baseline, as well as the change in these values from the baseline to the end of treatment. The table also displays the calcium multiplied by phosphorus ion product.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
